Senior Director, Global Value & Access Strategy – HIV Prevention at Gilead Sciences

Foster City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Ability to influence cross-functional leadership and enterprise decision making to optimise value, access and reimbursement
Ability to work closely with country teams to develop and implement global strategies and launch plans for HIV prevention
Experience across the full product lifecycle for HIV prevention assets, from early-stage pipeline through to launch and lifecycle management
Capability to represent and champion core global markets' needs in the development of global strategy and materials

Responsibilities

Develop and implement Global Value & Access (V&A) strategies, launch plans and lifecycle management to optimise access, reimbursement and uptake of Gilead’s HIV Prevention portfolio in core global markets
Represent global markets’ V&A perspective with comprehensive input to clinical development, program strategy and commercialisation teams, ensuring global payer/HTA perspectives and evidence requirements are reflected
Partner closely with Global HEOR and Global Pricing & Analytics to bring relevant insights and expertise to global teams and governance decisions
Co-lead the HIV Value & Access Strategy Team (VAST), engaging core markets to provide input to global strategy & deliverables
Collaborate with cross-functional partners/leaders in Global Strategic Marketing (GSM), Global Decision Science & Insights (GDSI), Global Medical Affairs (GMA), Government Affairs & Policy, Public Affairs and Regulatory Affairs to drive integrated HIV Prevention strategies
Cultivate close partnership with country general managers & cross-functional leadership in core markets to develop a deep understanding of their local environment & business needs
Bring the global V&A perspective towards internal and external communications planning
Co-lead (with Global Strategic Marketing) the development of cross-functional stakeholder engagement plans to shape the access and policy landscape for HIV Prevention
Lead payer, pricing & access and competitive research to understand value perception, landscape, evolving trends, value drivers and innovative pricing and access strategies

Skills

Value Strategy

Access Strategy

Reimbursement

HIV Prevention

Product Lifecycle Management

Cross-Functional Leadership

Launch Planning

Global Strategy

Pipeline Development

Stakeholder Influence

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free